These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16615098)

  • 21. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer.
    Pang ST; Weng WH; Flores-Morales A; Johansson B; Pourian MR; Nilsson P; Pousette A; Larsson C; Norstedt G
    Prostate; 2006 Feb; 66(2):157-72. PubMed ID: 16173030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.
    Xu XF; Zhou SW; Zhang X; Ye ZQ; Zhang JH; Ma X; Zheng T; Li HZ
    Asian J Androl; 2006 Jul; 8(4):455-62. PubMed ID: 16763722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular signatures of soy-derived phytochemicals in androgen-responsive prostate cancer cells: a comparison study using DNA microarray.
    Takahashi Y; Lavigne JA; Hursting SD; Chandramouli GV; Perkins SN; Kim YS; Wang TT
    Mol Carcinog; 2006 Dec; 45(12):943-56. PubMed ID: 16865672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microarray analysis of differential gene expression in androgen independent prostate cancer using a metastatic human prostate cancer cell line model.
    Balaji KC; Rao PS; Smith DJ; Louis S; Smith LM; Sherman S; Bacich D; O'Keefe D
    Urol Oncol; 2004; 22(4):313-20. PubMed ID: 15283889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
    Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.
    Koochekpour S; Lee TJ; Wang R; Sun Y; Delorme N; Hiraiwa M; Grabowski GA; Culig Z; Minokadeh A
    J Cell Biochem; 2007 Jun; 101(3):631-41. PubMed ID: 17171640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
    Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlating breakage-fusion-bridge events with the overall chromosomal instability and in vitro karyotype evolution in prostate cancer.
    Vukovic B; Beheshti B; Park P; Lim G; Bayani J; Zielenska M; Squire JA
    Cytogenet Genome Res; 2007; 116(1-2):1-11. PubMed ID: 17268171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
    Shigemura K; Sung SY; Kubo H; Arnold RS; Fujisawa M; Gotoh A; Zhau HE; Chung LW
    Prostate; 2007 May; 67(7):722-31. PubMed ID: 17342749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
    Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
    Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CCR2 expression correlates with prostate cancer progression.
    Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
    J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis.
    Narita S; Tsuchiya N; Saito M; Inoue T; Kumazawa T; Yuasa T; Nakamura A; Habuchi T
    Prostate; 2008 Feb; 68(3):321-35. PubMed ID: 18175332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PC-1/PrLZ contributes to malignant progression in prostate cancer.
    Zhang H; Wang J; Pang B; Liang RX; Li S; Huang PT; Wang R; Chung LW; Zhau HE; Huang C; Zhou JG
    Cancer Res; 2007 Sep; 67(18):8906-13. PubMed ID: 17875733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
    Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.
    Lapointe J; Malhotra S; Higgins JP; Bair E; Thompson M; Salari K; Giacomini CP; Ferrari M; Montgomery K; Tibshirani R; van de Rijn M; Brooks JD; Pollack JR
    Am J Surg Pathol; 2008 Feb; 32(2):205-9. PubMed ID: 18223322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
    Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
    Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells.
    Prasad M; Bernardini M; Tsalenko A; Marrano P; Paderova J; Lee CH; Ben-Dor A; Barrett MT; Squire JA
    Genes Chromosomes Cancer; 2008 May; 47(5):427-36. PubMed ID: 18273836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.